Indian Company’s Drug to Get ‘Orphan’ Drug Status by US FDA

Indian pharmaceutical company Natco Pharma’s new anti-cancer drug NRC-AN-019 has been accorded the orphan drug status by the US Food and Drug Administration (FDA). An orphan drug status is designated to a medicine which is useful for treating rare diseases that affect less than 2lakh people in the country. This drug is indicated in brain tumor (glioma), pancreatic cancer and chronic myelogenous leukemia.

Getting an orphan drug status entitles the manufacturers to special incentives which include 7years marketing exclusivity, specific tax credits and waiver of prescription drug user fee, which is about 1.5 million dollars per indication.

Anti-cancer drug
An experimental anti-cancer drug has shown effectiveness in treating a resistant type of lymphoma, according to a new report. Researchers say the

This is the first time that that an Indian company’s drug has been given an orphan drug status by the US FDA for 3clinical indications. The clinical trials for this drug are ongoing and the company expects to launch this medicine within 3years. This drug has been patented in 9countries including US.

Source-Medindia

Study Says Laser Beam Makes Cells 'Breathe In' Water and Potentially Anti-Cancer Drugs
Research indicates that shining a laser light on cells and then clicking off the light makes the cells breathe in surrounding water

Researchers Tweaking Medication To Synthesize Custom-Made Anti-Cancer Drug
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted

A New Anti-Cancer Drug Keeps Resistance Out
Dasatinib, developed by Bristol-Myers Squibb company offers a valuable treatment against chronic myeloid leukemia patients than the usual drug named Gleevec.